July 28, 2021 — The U.S. Justice Department announced earlier this month that St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act involving its implantable cardioverter defibrillators (ICD) and cardiac resyncronization therapy defibrillators (CRT-D). Between November 2014 and October 2016, the Justice Department said St.

July 28, 2021 - ScImage Inc., a provider of cloud-centric cardiovascular and radiology enterprise imaging and reporting solutions, announced a partnership with Cardiology Consultants PA (CCPA). The Spartanburg, S.C., cardiology group consists of 14 physicians, six nurse practitioners, three office locations and a newly opened office-based lab/ambulatory surgical center (OBL/ASC) servicing upstate South Carolina and western North Carolina.

Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21

July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them from the Heart Rhythm Society (HRS) 2021 meeting. For more information on the meeting, visit https://heartrhythm.com.

July 27, 2021 — AliveCor Inc., which offers FDA-cleared, smart-phone enabled personal electrocardiogram (ECG) technology and services, and Acutus Medical, an electrophysiology (EP) lab arrhythmia mapping company, announced a collaboration to assess the integration of data collection tools across the cardiology continuum of care that could potentially advance the field of arrhythmia treatment and disease management. 

July 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to a laser-assisted inferior vena cava (IVC) filter removal device developed by Philips Healthcare. The proposed device is intended for ablating tissue to remove an IVC filter when previous methods of remove it have failed.

July 27, 2021 -- Cardiovascular diseases account for 32% of global deaths. Myocardial infarction, or heart attacks, play a large part in heart diseases and the necrosis of cardiac tissue after blood supply is decreased or stopped.

In APL Bioengineering, by AIP Publishing, researchers from Pohang University of Science and Technology in South Korea take stock of stem cell-laden 3-D bioprinted cardiac patch technologies and their efficacy as a therapeutic and regenerative approach for ischemic cardiomyopathy in reversing scar formation and promoting myocardial regeneration.[1]

July 27, 2021 — Medtronic announced new data from the landmark WRAP-IT study published in Heart Rhythm,[1] demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the Tyrx Absorbable Antibacterial Envelope is used at implant.

Images or a digital twin mitral valve of a patient created from cardiac ultrasound that were used to perform a virtual surgical procedure to test how the intervention would impact the patient prior to actually performing the procedure. The right image shows color coding for sheer stresses on the valve leaflets before and after the virtual surgery. The right image shows the model quantitation of leaflet coaptation at peak systole prior to the the virtual surgery. Read the original article in Plos One https:/

Outside of medicine, computer-generated virtual twins of real machines like cars or airplanes have been used in engineering to allow modeling in a virtual environment. This is used for assessment of aerodynamics and to identify areas of sheer stresses and the performance of the machines under various conditions. In the past couple years, several medical companies have developed similar "digital twin" technology to computer model a patient's heart or other organs for use in a virtual test environment.

July 26, 2021 — Heart disease and stroke continue to kill more people in the U.S. than any other cause, despite, and likely even due to, the impact of the deadly COVID-19 pandemic last year. This is according to new provisional data released from the U.S Centers for Disease Control and Prevention (CDC).

July 26, 2021 – CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio System, making it more broadly available for coronary artery disease decision-making in Japan. The CathWorks FFRangio has already received regulatory approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in December 2019 and is also commercially available in the United States and Europe.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now